Antonina Shtilkind

Managing Member from Brillient

Brillient Vice President, Health Delivery

Ms. Nina Shtilkind is Brillient’s Vice President of Health Delivery and is responsible for delivering value on Brillient’s contracts with Department of Health and Human Services (HHS) agencies including the Food and Drug Administration (FDA) and the National Institutes of Health (NIH). With more than 25 years of experience in Federal Government contracting, she has supported many mission critical projects and programs in the Federal Government, simultaneously leading consulting teams in information technology, management consulting, and mission support projects.

Nina is an innovative business analyst and technology strategist, who played a primary role in developing numerous mission critical systems and applications, simplifying complex processes and procedures, and successfully implementing major multimillion projects for federal government agencies. She has expert knowledge of government regulatory compliance including FAR, FISMA, Privacy Act, Paperwork Reduction Act, Federal Records Act, and Service Contract Act. 

Nina was recognized as a finalist for the Washington Exec Pinnacle Award for Healthcare Executive of the Year in a Private Company in 2021 and 2022.

Nina holds a Master's degree in Mechanical Engineering and received her Project Management Professional (PMP) certification from the Project management Institute (PMI). She is an active member of PMI, Montgomery County and District of Columbia Chapters. 


Brillient

Brillient is driven by a sense of purpose – to protect, serve and care for the American people.

  • Brillient’s work in our national security sector enables the mission to protect the homeland.
  • Our civilian sector projects serve the country with revenue collection, financing small businesses, assisting citizens recover from disasters and securing the federal workforce.
  • Our healthcare sector work is focused on care for the American people protecting the nation’s food supply, ensuring quality medicines, lowering health costs and improving quality of care.

We need your consent to load the translations

We use a third-party service to translate the website content that may collect data about your activity. Please review the details in the privacy policy and accept the service to view the translations.